Technology Segment Analysis: Meibomian Gland Expression (MGX) (Largest Segment) vs Combination (MGX+IPL) (Fastest-Growing Segment)

Meibomian gland expression (MGX) dominated the dry eye treatment devices market, representing a 43.67% share in 2026. Its strong market position is supported by its direct focus on improving meibomian gland function, an important consideration in the management of evaporative dry eye symptoms. The technology provides a targeted approach for addressing gland dysfunction and can be incorporated into specialized ophthalmic treatment protocols. Increasing clinical attention to underlying causes of dry eye is supporting continued utilization of MGX-based devices.

Combination (MGX+IPL) is the fastest-growing technology segment as clinicians increasingly explore integrated approaches that address multiple contributing factors associated with dry eye. Combining meibomian gland expression with intense pulsed light therapy can provide a broader treatment strategy than relying on a single modality. Growing interest in comprehensive dry eye management and technology combinations that can address different aspects of the condition is creating additional momentum for integrated treatment platforms.

End-use Segment Analysis: Hospitals (Largest Segment) vs Ophthalmic Clinics (Fastest-Growing Segment)

Hospitals held the largest position in the dry eye treatment devices market in 2026, reflecting their broad clinical infrastructure and access to specialized ophthalmic services. Hospitals can support diagnosis and treatment through multidisciplinary facilities, specialized equipment, and trained ophthalmic professionals. Their ability to manage patients with varying levels of ocular care needs provides a strong foundation for device utilization, while increasing attention to structured treatment of chronic eye conditions sustains demand in hospital environments.

Ophthalmic clinics represent the fastest-growing end-use segment as eye-care services increasingly shift toward specialized, focused treatment environments. Dedicated ophthalmic clinics can provide convenient access to dry eye assessment and device-based procedures while enabling streamlined care by specialized practitioners. Rising patient preference for accessible specialty care and growing adoption of targeted dry eye treatment technologies are supporting the expansion of ophthalmic clinics within this market.